Table 1 Trials' Characteristics
Authors | Pts | Prior chemotherapy lines for metastatic disease | Arms | > 3 sites | No adjuvant Chemo | Visceral site | Hormonal Receptors Negative (RN) | Prior taxanes (T) | Prior Anthra (A) |
|---|---|---|---|---|---|---|---|---|---|
Miller et al | 462 | Mostly 1-2 | Cap (2,500 mg/m2/day, days 1-14) Cap (2,500 mg/m2/day, days 1-14) + Beva (15 mg/kg) | 49.7% | NR | 78.7% | NR | 100% | 100% |
Gray et al | 722 | 0 | wPac (90 mg/m2 day 1, 8 and 15)wPac (90 mg/m2 day 1, 8 and 15)+ Beva (10 mg/kg) | 45.7% | 34.2% | 62.2% | 36.7% | 14.9% | 37.2% |
Miles et al | 736 | 0 | Doc (100 mg/m2) Doc (100 mg/m2)+ Beva 7.5 (7.5 mg/kg) Doc (100 mg/m2)+ Beva 15 (15 mg/kg) | 35.0% 33.4% | 54.8% 54.9% | NR | 17.1% 17.1% | 14.9% 16.2% | 53.7% 53.5% |
Dieras et al | 622 615 | 0 | A/T A/T + Beva (15 mg/kg) Cap (2,000 mg/m2/day, days 1-14) Cap (2,000 mg/m2/day, days 1-14) + Beva (15 mg/kg) | 54.5% 27.8% | 45.2% 43.9% | 70.4% 68.8% | 24.0% 23.6% | 15.0% 39.5% | 29.9% 62.9% |
Bruwski et al | 684 | 1 | Chemo Chemo + Beva | 45.3% | NR | 73.1% | 27.7% | NR | NR |